Comparative Pharmacology
Head-to-head clinical analysis: MORPHINE SULFATE versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MORPHINE SULFATE versus WESTADONE.
MORPHINE SULFATE vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at mu, kappa, and delta opioid receptors in the central nervous system, mimicking endogenous endorphins. Primarily mu-receptor activation leads to analgesia by inhibiting adenylate cyclase, decreasing cAMP, and modulating ion channels (e.g., opening GIRK channels, closing voltage-gated calcium channels), reducing neurotransmitter release.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
5-10 mg intravenously every 4 hours as needed; 10-30 mg orally every 4 hours as needed; 0.1-0.2 mg/kg intramuscularly every 4 hours as needed.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in adults; prolonged in neonates (6-8 hours), elderly, and renal impairment (up to 15 hours).
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Renal: 90% (primarily as morphine-3-glucuronide and morphine-6-glucuronide, with 10% unchanged); Biliary/Fecal: 7-10%.
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category D/X
Category C
Opioid Agonist
Opioid Agonist